Processa Pharmaceuticals, Inc. (PCSA)
PCSA Stock Price Chart
Explore Processa Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze PCSA price movements and trends.
PCSA Company Profile
Discover essential business fundamentals and corporate details for Processa Pharmaceuticals, Inc. (PCSA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Mar 2014
Employees
10.00
CEO
George K. Ng
Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
PCSA Financial Timeline
Browse a chronological timeline of Processa Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.08.
Earnings released on 7 Aug 2025
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%.
Earnings released on 8 May 2025
EPS came in at -$0.30 surpassing the estimated -$0.77 by +61.04%.
Earnings released on 20 Mar 2025
EPS came in at -$0.74 surpassing the estimated -$0.92 by +19.57%, while revenue for the quarter reached $12.47M .
Earnings released on 30 Oct 2024
EPS came in at -$1.03 falling short of the estimated -$1.00 by -3.00%.
Earnings released on 13 Aug 2024
EPS came in at -$1.01 falling short of the estimated -$0.98 by -3.06%.
Earnings released on 10 May 2024
EPS came in at -$1.11 surpassing the estimated -$1.18 by +5.93%.
Earnings released on 29 Mar 2024
EPS came in at -$0.24 surpassing the estimated -$1.60 by +85.00%.
Stock split effective on 22 Jan 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$1.60 falling short of the estimated -$0.10 by -1.50K%.
Earnings released on 10 Aug 2023
EPS came in at -$2.00 surpassing the estimated -$3.00 by +33.33%.
Earnings released on 15 May 2023
EPS came in at -$3.60 surpassing the estimated -$5.60 by +35.71%.
Earnings released on 30 Mar 2023
EPS came in at -$7.00 falling short of the estimated -$5.00 by -40.00%.
Earnings released on 8 Nov 2022
EPS came in at -$7.40 falling short of the estimated -$6.80 by -8.82%.
Earnings released on 12 Aug 2022
EPS came in at -$6.40 falling short of the estimated -$0.20 by -3.10K%.
Earnings released on 12 May 2022
EPS came in at -$4.00 surpassing the estimated -$4.80 by +16.67%.
Earnings released on 30 Mar 2022
EPS came in at -$4.20 falling short of the estimated -$3.60 by -16.67%, while revenue for the quarter reached $175.40K .
Earnings released on 12 Nov 2021
EPS came in at -$3.80 surpassing the estimated -$4.20 by +9.52%.
Earnings released on 12 Aug 2021
EPS came in at -$4.00 falling short of the estimated -$3.00 by -33.33%.
Earnings released on 13 May 2021
EPS came in at -$2.80 falling short of the estimated -$0.10 by -2.70K%.
Earnings released on 25 Mar 2021
EPS came in at -$18.00 falling short of the estimated -$0.35 by -5.04K%, while revenue for the quarter reached -$277.95K .
Earnings released on 12 Nov 2020
EPS came in at -$11.00 falling short of the estimated -$0.16 by -6.78K%.
PCSA Stock Performance
Access detailed PCSA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.